Nature Communications (Oct 2018)
LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway
- Ang Gao,
- Tonghua Sun,
- Gui Ma,
- Jiangran Cao,
- Qingxia Hu,
- Ling Chen,
- Yanxin Wang,
- Qianying Wang,
- Jiafu Sun,
- Rui Wu,
- Qiao Wu,
- Jiaxi Zhou,
- Lin Liu,
- Junjie Hu,
- Jin-Tang Dong,
- Zhengmao Zhu
Affiliations
- Ang Gao
- Department of Genetics and Cell Biology, College of Life Sciences, Nankai University
- Tonghua Sun
- Department of Genetics and Cell Biology, College of Life Sciences, Nankai University
- Gui Ma
- Department of Genetics and Cell Biology, College of Life Sciences, Nankai University
- Jiangran Cao
- Department of Genetics and Cell Biology, College of Life Sciences, Nankai University
- Qingxia Hu
- Department of Genetics and Cell Biology, College of Life Sciences, Nankai University
- Ling Chen
- Department of Pathology, Tianjin Central Hospital of Gynecology and Obstetrics
- Yanxin Wang
- Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore
- Qianying Wang
- Department of Genetics and Cell Biology, College of Life Sciences, Nankai University
- Jiafu Sun
- Department of Genetics and Cell Biology, College of Life Sciences, Nankai University
- Rui Wu
- Department of Genetics and Cell Biology, College of Life Sciences, Nankai University
- Qiao Wu
- Department of Genetics and Cell Biology, College of Life Sciences, Nankai University
- Jiaxi Zhou
- State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
- Lin Liu
- Department of Genetics and Cell Biology, College of Life Sciences, Nankai University
- Junjie Hu
- Department of Genetics and Cell Biology, College of Life Sciences, Nankai University
- Jin-Tang Dong
- Department of Genetics and Cell Biology, College of Life Sciences, Nankai University
- Zhengmao Zhu
- Department of Genetics and Cell Biology, College of Life Sciences, Nankai University
- DOI
- https://doi.org/10.1038/s41467-018-06309-8
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 17
Abstract
Tamoxifen resistance is a major problem in the treatment of ERa positive breast cancer. Here, the authors show that LEM4 confers tamoxifen resistance by activating the cyclin D-CDK4/6-Rb axis and ERa signaling in endocrine-resistant breast cancer.
